SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2191727

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2191727

U.S. Contraceptives Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3250
PDF & Excel (Multi User License)
USD 4450
PDF & Excel (Enterprise User License)
USD 5750

Add to Cart

The U.S. Contraceptives Market reached USD 6.60 billion in 2025 and is projected to grow at 3.9% CAGR from 2026 to 2035. The market is expected to cross USD 9.68 billion valuation by 2035. Purchasing routes span clinician-administered devices, prescriptions, mass-retail products, and digital care. Differences in insurance coverage, procedure access, and consumer-directed purchasing create distinct commercial conditions across categories rather than a uniform market for all contraceptive products.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$6.60 Billion
Forecast Value$9.68 Billion
CAGR3.9%

Insurance coverage supports access to methods that otherwise involve substantial upfront payment or a clinical encounter. When cost-sharing falls, selection can place greater weight on user preferences, tolerability, and duration. Telehealth reduces appointment, transport, and scheduling burdens for products that do not require an in-person procedure. Its continued contribution depends on reimbursement and prescribing arrangements across jurisdictions. Nonprescription daily-pill authorization adds a retail channel outside the conventional prescription process. This changes how suppliers reach users facing time or geographic constraints. Broader pharmacy prescribing can further widen access, making distribution architecture and coverage as consequential to demand as awareness of individual contraceptive methods.

Based on product type, hormonal intrauterine devices are projected to reach USD 2.10 billion by 2035. Familiarity among clinicians, reimbursement-supported placement, and demand for reversible methods without daily administration support this category. Commercial access still requires the availability of insertion services, connecting product demand with provider capacity and established clinical channels. Manufacturers need to maintain engagement and support around these procedure-linked purchases. The segment's position reflects a preference for reducing ongoing adherence demands, while access and payment arrangements determine whether interest can become completed placement. This creates a different market model from retail products that consumers can obtain without a procedure.

By age group, users aged 15-44 years generated USD 5.84 billion in 2025. This cohort supports ongoing demand across devices, prescriptions, retail outlets, and digital channels. Its importance makes changes in payer policy or access arrangements particularly consequential for overall purchasing. Suppliers need to address several acquisition routes rather than rely on a single distribution model. Product categories within the cohort differ in how often purchases occur and whether professional involvement is required. Manufacturers and service providers therefore compete through coverage familiarity, channel accessibility, and support suited to the method, connecting commercial execution with the practical steps users must take to obtain contraception.

The Northeast U.S. contraceptives market is projected to reach USD 1.74 billion by 2035. Dense provider networks, established family-planning services, and commercial insurance participation support prescriptions and clinician-administered methods. Digital care complements local capacity rather than replacing the need for procedures. Suppliers can work within a mature access environment, but still need to connect product availability with reimbursement and provider engagement. The regional opportunity includes continuing utilization through established systems as well as digital channels that reduce appointment friction. Its combination of clinical infrastructure and coverage supports a varied purchasing base across methods with different service requirements and consumer acquisition pathways.

Organon and Co. held 12.3% market share in 2025. Its women's-health position and Nexplanon implant franchise connect the company with long-acting reversible contraception and the associated provider and reimbursement environment. Training support and clinician engagement are important to maintaining a procedure-linked business. Its commercial position depends on more than consumer brand awareness because adoption requires access to qualified services and familiarity among providers. This gives established relationships a meaningful role in defending the franchise. The company's strategy reflects the need to support the clinical pathway around a device while responding to changes in the competitive and market-access environment.

Some of the major players in this market are Church and Dwight Co. Inc., Bayer AG, Viatris Inc., CooperSurgical Inc., Pfizer Inc., AbbVie Inc., Afaxys Inc., Reckitt Benckiser Group plc, Agile Therapeutics Inc., Evofem Biosciences Inc., Mayer Laboratories Inc., and Femasys Inc. Competition varies between branded devices, generic prescriptions, and retail consumer products. Device suppliers emphasize provider relationships and access, while generic businesses operate within price-sensitive formularies. Condom and other retail brands rely more heavily on distribution, recognition, and repeat purchases. These differing routes create room for companies with specialized commercial capabilities across the broader reproductive-health market.

Product Code: 11769

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research Approach
  • 1.2 Quality Commitments
    • 1.2.1 GMI AI Policy & Data Integrity Commitment
      • 1.2.1.1 Source Consistency Protocol
  • 1.3 Research Trail & Confidence Scoring
    • 1.3.1 Research Trail Components
    • 1.3.2 Scoring Components
  • 1.4 Data Collection
    • 1.4.1 Partial List of Primary Sources
  • 1.5 Data Mining Sources
    • 1.5.1 Paid Sources
      • 1.5.1.1 Sources, by Region
  • 1.6 Base Estimates & Calculations
    • 1.6.1 Base Year Calculation
  • 1.7 Forecast Model
    • 1.7.1 Quantified Market Impact Analysis
      • 1.7.1.1 Mathematical Impact of Growth Parameters on Forecast
  • 1.8 Research Transparency Addendum
    • 1.8.1 Source Attribution Framework
    • 1.8.2 Quality Assurance Metrics
    • 1.8.3 Our Commitment to Trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° Synopsis
  • 2.2 Key Market Trends
    • 2.2.1 Product Type Trends (Chapter 5 - By Product Type)
    • 2.2.2 Age Group Trends (Chapter 6 - By Age Group)
    • 2.2.3 Distribution Channel Trends (Chapter 7 - By Distribution Channel)
    • 2.2.4 Zone Trends (Chapter 8 - By Zone)
  • 2.3 TAM Analysis, 2027-2035
  • 2.4 CXO Perspectives: Strategic Imperatives

Chapter 3. Industry Insights

  • 3.1 Industry Ecosystem Analysis
    • 3.1.1 Supplier Landscape
    • 3.1.2 Profit Margin
    • 3.1.3 Cost Structure
    • 3.1.4 Value Addition at Each Stage
    • 3.1.5 Factors Affecting the Value Chain
    • 3.1.6 Disruptions
  • 3.2 Industry Impact Forces
    • 3.2.1 Growth Drivers
      • 3.2.1.1 Rising Demand for LARCs Post-Dobbs Decision - Shift Toward Long-Term Contraception
      • 3.2.1.2 OTC Oral Contraceptive Approval (Opill, 2023) Expanding Consumer Access
      • 3.2.1.3 ACA Mandated Insurance Coverage Reducing Cost Barriers
      • 3.2.1.4 Expansion of Telehealth & Direct-to-Consumer Contraceptive Platforms
      • 3.2.1.5 Government Funding Through Title X & Medicaid Supporting Access for Low-Income Populations
    • 3.2.2 Industry Pitfalls & Challenges
      • 3.2.2.1 Adverse Side Effects of Hormonal Contraceptives Limiting Adoption & Compliance
      • 3.2.2.2 State-Level Legislative Uncertainty Creating Demand Volatility
      • 3.2.2.3 Complex & Lengthy FDA Approval Process Slowing Innovation Entry
      • 3.2.2.4 Persistent Stigma & Cultural Barriers in Conservative Communities
      • 3.2.2.5 Contraceptive Deserts - 51% of the U.S. Lacking Adequate Clinic Access
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Male Contraceptive Pipeline - Untapped Market Segment
      • 3.2.3.2 Pharmacist-Prescribing Expansion - 38 States + DC Now Authorized
      • 3.2.3.3 Underserved Rural & Low-Income Populations Representing Addressable Access Gap
      • 3.2.3.4 Non-Hormonal Contraceptive Innovation (Phexxi, Copper-Based) Addressing Hormone-Averse Consumers
  • 3.3 Growth Potential Analysis
  • 3.4 Pricing Analysis (Driven by Primary Research)
    • 3.4.1 Historical Price Trend Analysis (Driven by Primary Research)
    • 3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus) (Driven by Primary Research)
    • 3.4.3 Insurance & Medicaid Reimbursement Impact on Net Pricing
    • 3.4.4 Out-of-Pocket Cost Comparison Across Product Categories
  • 3.5 Regulatory Landscape
    • 3.5.1 FDA Drug & Device Approval Pathways for Contraceptives
    • 3.5.2 ACA Contraceptive Mandate & Insurance Coverage Requirements
    • 3.5.3 State-Level Regulatory Divergence Post-Dobbs Decision
    • 3.5.4 Title X Family Planning Program & Medicaid Contraceptive Coverage Rules
    • 3.5.5 OTC Approval Pathways & Pharmacist-Prescribing Authorization (38 States + DC)
  • 3.6 Porter's Analysis
    • 3.6.1 Bargaining Power of Suppliers
    • 3.6.2 Bargaining Power of Buyers
    • 3.6.3 Threat of New Entrants
    • 3.6.4 Threat of Substitute Products/Services
    • 3.6.5 Intensity of Competitive Rivalry
  • 3.7 PESTEL Analysis
    • 3.7.1 Political Factors (Federal & State Policy on Reproductive Rights)
    • 3.7.2 Economic Factors (Healthcare Spending, Insurance Penetration)
    • 3.7.3 Social Factors (Awareness, Stigma, Cultural Attitudes)
    • 3.7.4 Technological Factors (OTC Expansion, Telehealth, Innovation)
    • 3.7.5 Environmental Factors (Pharmaceutical Waste & Disposal Regulations)
    • 3.7.6 Legal Factors (Dobbs Decision Fallout, State Abortion-Contraceptive Laws)
  • 3.8 Trade Data Analysis (Based on Paid Database)
    • 3.8.1 Import/Export Volume & Value Trends
    • 3.8.2 Key Trade Corridors & Tariff Impact
  • 3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
    • 3.9.1 AI-Driven Disruption of Existing Business Models
    • 3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
    • 3.9.3 Risks, Limitations & Regulatory Considerations
  • 3.10 Patent Landscape (Driven by Primary Research)
    • 3.10.1 Active Patent Portfolio by Product Category
    • 3.10.2 Patent Expiry Analysis & Generic Entry Timeline
    • 3.10.3 Key Innovation White Spaces & Filing Trends
  • 3.11 Investment & Funding Analysis
    • 3.11.1 Venture Capital & Private Equity Activity in Contraceptive Startups
    • 3.11.2 Public Funding - NIH, HHS & Title X Allocations
    • 3.11.3 R&D Spend Benchmarking by Key Players
  • 3.12 Future Outlook & Opportunities
    • 3.12.1 Non-Hormonal Contraceptive Innovation as Next Growth Wave
    • 3.12.2 Male Contraceptive Commercialization Timeline
    • 3.12.3 Telehealth-Led Prescription Model Reshaping Distribution
    • 3.12.4 State-Level Policy Divergence Creating Asymmetric Growth Corridors

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company Market Share Analysis, 2025
    • 4.2.1 Market Concentration Analysis
  • 4.3 Competitive Analysis of Major Market Players
  • 4.4 Competitive Positioning Matrix
  • 4.5 Key Developments
    • 4.5.1 Mergers & Acquisitions
    • 4.5.2 Partnerships & Collaborations
    • 4.5.3 New Product Launches
    • 4.5.4 Expansion Plans & Funding
  • 4.6 Company Tier Benchmarking
    • 4.6.1 Tier Classification Criteria & Qualifying Thresholds
    • 4.6.2 Tier Positioning Matrix by Revenue, Geography & Innovation

Chapter 5. U.S. Contraceptives Market Estimates & Forecast, By Product Type (USD Million, 2022-2035)

  • 5.1 Devices
    • 5.1.1 Condoms
      • 5.1.1.1 Male
      • 5.1.1.2 Female
    • 5.1.2 Intrauterine Devices (IUDs)
      • 5.1.2.1 Hormonal IUD
      • 5.1.2.2 Copper (Non-Hormonal) IUD
    • 5.1.3 Vaginal Rings
    • 5.1.4 Subdermal Implants
    • 5.1.5 Diaphragms
    • 5.1.6 Other Devices
  • 5.2 Drugs
    • 5.2.1 Oral Contraceptive Pills
    • 5.2.2 Injectable Contraceptives
    • 5.2.3 Transdermal Patches
    • 5.2.4 Topical Gel, Foam & Spermicides
    • 5.2.5 Emergency Contraceptive Pills

Chapter 6. U.S. Contraceptives Market Estimates & Forecast, By Age Group (USD Million, 2022-2035)

  • 6.1 15-44 Years
  • 6.2 Above 44 Years

Chapter 7. U.S. Contraceptives Market Estimates & Forecast, By Distribution Channel (USD Million, 2022-2035)

  • 7.1 Retail Pharmacies
  • 7.2 Hospital Pharmacies
  • 7.3 Online Channels
  • 7.4 Other Distribution Channels

Chapter 8. U.S. Contraceptives Market Estimates & Forecast, By Zone (USD Million, 2022-2035)

  • 8.1 Key Trends
  • 8.2 Zones
    • 8.2.1 East North Central
      • 8.2.1.1 Illinois
      • 8.2.1.2 Indiana
      • 8.2.1.3 Michigan
      • 8.2.1.4 Ohio
      • 8.2.1.5 Wisconsin
    • 8.2.2 West South Central
      • 8.2.2.1 Arkansas
      • 8.2.2.2 Louisiana
      • 8.2.2.3 Oklahoma
      • 8.2.2.4 Texas
    • 8.2.3 South Atlantic
      • 8.2.3.1 Delaware
      • 8.2.3.2 Florida
      • 8.2.3.3 Georgia
      • 8.2.3.4 Maryland
      • 8.2.3.5 North Carolina
      • 8.2.3.6 South Carolina
      • 8.2.3.7 Virginia
      • 8.2.3.8 West Virginia
      • 8.2.3.9 Washington, D.C.
    • 8.2.4 Northeast
      • 8.2.4.1 Connecticut
      • 8.2.4.2 Maine
      • 8.2.4.3 Massachusetts
      • 8.2.4.4 New Hampshire
      • 8.2.4.5 Rhode Island
      • 8.2.4.6 Vermont
      • 8.2.4.7 New Jersey
      • 8.2.4.8 New York
      • 8.2.4.9 Pennsylvania
    • 8.2.5 East South Central
      • 8.2.5.1 Alabama
      • 8.2.5.2 Kentucky
      • 8.2.5.3 Mississippi
      • 8.2.5.4 Tennessee
    • 8.2.6 West North Central
      • 8.2.6.1 Iowa
      • 8.2.6.2 Kansas
      • 8.2.6.3 Minnesota
      • 8.2.6.4 Missouri
      • 8.2.6.5 Nebraska
      • 8.2.6.6 North Dakota
      • 8.2.6.7 South Dakota
    • 8.2.7 Pacific Central
      • 8.2.7.1 Alaska
      • 8.2.7.2 California
      • 8.2.7.3 Hawaii
      • 8.2.7.4 Oregon
      • 8.2.7.5 Washington
    • 8.2.8 Mountain States
      • 8.2.8.1 Arizona
      • 8.2.8.2 Colorado
      • 8.2.8.3 Utah
      • 8.2.8.4 Nevada
      • 8.2.8.5 New Mexico
      • 8.2.8.6 Idaho
      • 8.2.8.7 Montana
      • 8.2.8.8 Wyoming

Chapter 9. Company Profiles (Driven by Primary Research)

  • 9.1 Top Global Players
    • 9.1.1 Bayer AG
    • 9.1.2 Organon & Co.
    • 9.1.3 Pfizer Inc.
    • 9.1.4 AbbVie Inc.
    • 9.1.5 Viatris Inc.
  • 9.2 Regional Players
    • 9.2.1 CooperSurgical Inc.
    • 9.2.2 Afaxys Inc.
    • 9.2.3 Church & Dwight Co. Inc.
    • 9.2.4 Reckitt Benckiser Group plc
  • 9.3 Emerging Players
    • 9.3.1 Agile Therapeutics Inc.
    • 9.3.2 Evofem Biosciences Inc.
    • 9.3.3 Mayer Laboratories Inc.
    • 9.3.4 Femasys Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!